HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3,4,5,6-tetrahydroxyxanthone

Networked: 2 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 3-Ring Heterocyclic Compounds
    - Xanthenes: 65
      - Xanthones: 211
        3,4,5,6-tetrahydroxyxanthone: 2

Experts

1.	Hu, Ya-Ping: 1 article (12/2008)
2.	Li, Da-Zhi: 1 article (12/2008)
3.	Lu, Xiang-Yang: 1 article (12/2008)
4.	Sun, Zhi-Liang: 1 article (12/2008)
5.	Xiao, Hong-Bo: 1 article (12/2008)
6.	Xu, Jian-Ping: 1 article (12/2008)
7.	Dai, Zhong: 1 article (07/2004)
8.	Du, Yan-Hua: 1 article (07/2004)
9.	Hu, Chang-Ping: 1 article (07/2004)
10.	Hu, Gao-Yun: 1 article (07/2004)

Related Diseases

1.	Myocardial Ischemia (Ischemic Heart Diseases) 07/01/2004 - "3,4,5,6-Tetrahydroxyxanthone protects against myocardial ischemia-reperfusion injury in rats." 07/01/2004 - "In the present study, we tested the protective effect of 3,4,5,6-tetrahydroxyxanthone, a synthetic xanthone derivative, on myocardial ischemia-reperfusion injury in rats. " 07/01/2004 - "These results suggest that 3,4,5,6-tetrahydroxyxanthone possesses a protective effect on myocardial ischemia-reperfusion injury, and that the protective effects of 3,4,5,6-tetrahydroxyxanthone may be related to inhibition of TNF-alpha production and stimulation of IL-6 generation by inhibition of ROS production."
2.	Reperfusion Injury 07/01/2004 - "3,4,5,6-Tetrahydroxyxanthone protects against myocardial ischemia-reperfusion injury in rats." 07/01/2004 - "In the present study, we tested the protective effect of 3,4,5,6-tetrahydroxyxanthone, a synthetic xanthone derivative, on myocardial ischemia-reperfusion injury in rats. " 07/01/2004 - "These results suggest that 3,4,5,6-tetrahydroxyxanthone possesses a protective effect on myocardial ischemia-reperfusion injury, and that the protective effects of 3,4,5,6-tetrahydroxyxanthone may be related to inhibition of TNF-alpha production and stimulation of IL-6 generation by inhibition of ROS production."
3.	Dyslipidemias (Dyslipidemia) 12/01/2008 - "The present results suggest that the beneficial effect of 3,4,5,6-tetrahydroxyxanthone on dyslipidemia may be related to reduced expression of Angptl3." 12/01/2008 - "Beneficial effect of 3,4,5,6-tetrahydroxyxanthone on dyslipidemia in apolipoprotein E-deficient mice." 12/01/2008 - "The present study was conducted to test the effect of 3,4,5,6-tetrahydroxyxanthone, a xanthone compound, on dyslipidemia in apolipoprotein E-deficient (ApoE-/-) mice. "
4.	Infarction (Infarctions) 07/01/2004 - "3,4,5,6-tetrahydroxyxanthone (0.5 or 1.0 mg/kg, i.v.) also markedly decreased infarct size and the release of creatine kinase and TNF-alpha, and increased serum IL-6 level in vivo. "

Related Drugs and Biologics

1.	Interleukin-6 (Interleukin 6)
2.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
3.	xanthone
4.	Apolipoproteins E (ApoE)
5.	Apolipoproteins
6.	Creatine Kinase (Creatine Phosphokinase)